Zacks - Titan Pharmaceuticals Inc. (TTNP) FDA Approves Probuphine, partner outlines development plan, target price increases to $12.00.

Report

Zacks

FDA Approves Probuphine, partner outlines development plan, target price increases to $12.00.

03/06/2016 6 EN

Underlying

Titan Pharmaceuticals Inc.

Titan Pharmaceuticals is a pharmaceutical company developing proprietary therapeutics for the treatment of serious medical disorders. The company's product development programs utilize its proprietary drug delivery platform, ProNeura

See profile

US8883143096 United States

Provider

Zacks

Zacks Investment Research is a Chicago based firm with over 30 years of experience in providing institutional and individual investors with the analytical tools and financial information necessary to the success of their investment process.

See profile

Other Reports on these Companies

SmartInsider

Titan Pharmaceuticals Inc: 1 director

A director at Titan Pharmaceuticals Inc sold 3,747,968 shares at 1.230USD and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The ...

Free Trial

June 24, 2023 June 24, 2023 1 EN

Zacks

TTNP: Coronavirus Delays European Launch

May 18, 2020 May 18, 2020 7 EN

Zacks

TTNP: Stepping Into Stability

April 2, 2020 April 2, 2020 8 EN

PBSV: Steady as she goes

July 24, 2020 July 24, 2020 5 EN

BCLI: KOL Event Gives Overview of the use of NurOwnÂ® in Alzheimerâ€™s Disease; Raising Valuation to $25/Share...

July 9, 2020 July 9, 2020 7 EN

MNOV: FDA Gives OK to Initiate Clinical Trial of MN-166 to Prevent ARDS in COVID- 19 Patients...

July 2, 2020 July 2, 2020 7 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

FDA Approves Probuphine, partner outlines development plan, target price increases to $12.00.

Titan Pharmaceuticals Inc: 1 director

TTNP: Coronavirus Delays European Launch

TTNP: Stepping Into Stability

PBSV: Steady as she goes

BCLI: KOL Event Gives Overview of the use of NurOwnÂ® in Alzheimerâ€™s Disease; Raising Valuation to $25/Share...

MNOV: FDA Gives OK to Initiate Clinical Trial of MN-166 to Prevent ARDS in COVID- 19 Patients...

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe